Then, IGF2BP2 was highly expressed in thyroid cancer, and MALAT1 was found to up-regulate IGF2BP2 and enhance MYC expression via m6A modification recognition by competitively binding to miR-204 [38]. This evidence concerns the gene MYC and thyroid gland carcinoma.